Immunoregulatory peptides and methods of use
First Claim
Patent Images
1. A pharmaceutical peptide composition comprising:
- a peptide-transducing sequence conjugate, wherein the peptide comprises SEQ ID NO;
337, and wherein the peptide is conjugated to the transducing sequence at the peptide C-terminus; and
a pharmaceutically-acceptable excipient, wherein the pharmaceutical composition is in a unit dosage form.
1 Assignment
0 Petitions
Accused Products
Abstract
Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.
-
Citations
21 Claims
-
1. A pharmaceutical peptide composition comprising:
- a peptide-transducing sequence conjugate, wherein the peptide comprises SEQ ID NO;
337, and wherein the peptide is conjugated to the transducing sequence at the peptide C-terminus; and
a pharmaceutically-acceptable excipient, wherein the pharmaceutical composition is in a unit dosage form. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- a peptide-transducing sequence conjugate, wherein the peptide comprises SEQ ID NO;
-
12. A synthetic peptide of SEQ ID NO:
- 337, conjugated to a transducing sequence at the C-terminus; and
wherein at least one amino acid residue of the synthetic peptide is in the D-configuration. - View Dependent Claims (13)
- 337, conjugated to a transducing sequence at the C-terminus; and
-
14. A synthetic peptide-transducing sequence conjugate, wherein the synthetic peptide comprises SEQ ID NO:
- 337, and wherein the synthetic peptide is conjugated to the transducing sequence at the peptide C-terminus.
- View Dependent Claims (15, 16, 17, 18, 19, 20, 21)
Specification